YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy
BackgroundYTH N6-methyladenosine RNA binding protein 1 (YTHDF1) has been indicated proven to participate in the cross-presentation of tumor antigens in dendritic cells and the cross-priming of CD8+ T cells. However, the role of YTHDF1 in prognosis and immunology in human cancers remains largely unkn...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.607224/full |
| _version_ | 1818642550451339264 |
|---|---|
| author | Jian Hu Dongxu Qiu Anze Yu Jiao Hu Hao Deng Huihuang Li Zhenglin Yi Jinbo Chen Xiongbing Zu |
| author_facet | Jian Hu Dongxu Qiu Anze Yu Jiao Hu Hao Deng Huihuang Li Zhenglin Yi Jinbo Chen Xiongbing Zu |
| author_sort | Jian Hu |
| collection | DOAJ |
| description | BackgroundYTH N6-methyladenosine RNA binding protein 1 (YTHDF1) has been indicated proven to participate in the cross-presentation of tumor antigens in dendritic cells and the cross-priming of CD8+ T cells. However, the role of YTHDF1 in prognosis and immunology in human cancers remains largely unknown.MethodsAll original data were downloaded from TCGA and GEO databases and integrated via R 3.2.2. YTHDF1 expression was explored with the Oncomine, TIMER, GEPIA, and BioGPS databases. The effect of YTHDF1 on prognosis was analyzed via GEPIA, Kaplan-Meier plotter, and the PrognoScan database. The TISIDB database was used to determine YTHDF1 expression in different immune and molecular subtypes of human cancers. The correlations between YTHDF1 expression and immune checkpoints (ICP), tumor mutational burden (TMB), microsatellite instability (MSI), and neoantigens in human cancers were analyzed via the SangerBox database. The relationships between YTHDF1 expression and tumor-infiltrated immune cells were analyzed via the TIMER and GEPIA databases. The relationships between YTHDF1 and marker genes of tumor-infiltrated immune cells in urogenital cancers were analyzed for confirmation. The genomic alterations of YTHDF1 were investigated with the c-BioPortal database. The differential expression of YTHDF1 in urogenital cancers with different clinical characteristics was analyzed with the UALCAN database. YTHDF1 coexpression networks were studied by the LinkedOmics database.ResultsIn general, YTHDF1 expression was higher in tumors than in paired normal tissue in human cancers. YTHDF1 expression had strong relationships with prognosis, ICP, TMB, MSI, and neoantigens. YTHDF1 plays an essential role in the tumor microenvironment (TME) and participates in immune regulation. Furthermore, significant strong correlations between YTHDF1 expression and tumor immune-infiltrated cells (TILs) existed in human cancers, and marker genes of TILs were significantly related to YTHDF expression in urogenital cancers. TYHDF1 coexpression networks mostly participated in the regulation of immune response and antigen processing and presentation.ConclusionYTHDF1 may serve as a potential prognostic and immunological pan-cancer biomarker. Moreover, YTHDF1 could be a novel target for tumor immunotherapy. |
| first_indexed | 2024-12-16T23:44:51Z |
| format | Article |
| id | doaj.art-221108f2bb514acfa18ce2a2ee2ff304 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-16T23:44:51Z |
| publishDate | 2021-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-221108f2bb514acfa18ce2a2ee2ff3042022-12-21T22:11:31ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-05-011110.3389/fonc.2021.607224607224YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and ImmunotherapyJian HuDongxu QiuAnze YuJiao HuHao DengHuihuang LiZhenglin YiJinbo ChenXiongbing ZuBackgroundYTH N6-methyladenosine RNA binding protein 1 (YTHDF1) has been indicated proven to participate in the cross-presentation of tumor antigens in dendritic cells and the cross-priming of CD8+ T cells. However, the role of YTHDF1 in prognosis and immunology in human cancers remains largely unknown.MethodsAll original data were downloaded from TCGA and GEO databases and integrated via R 3.2.2. YTHDF1 expression was explored with the Oncomine, TIMER, GEPIA, and BioGPS databases. The effect of YTHDF1 on prognosis was analyzed via GEPIA, Kaplan-Meier plotter, and the PrognoScan database. The TISIDB database was used to determine YTHDF1 expression in different immune and molecular subtypes of human cancers. The correlations between YTHDF1 expression and immune checkpoints (ICP), tumor mutational burden (TMB), microsatellite instability (MSI), and neoantigens in human cancers were analyzed via the SangerBox database. The relationships between YTHDF1 expression and tumor-infiltrated immune cells were analyzed via the TIMER and GEPIA databases. The relationships between YTHDF1 and marker genes of tumor-infiltrated immune cells in urogenital cancers were analyzed for confirmation. The genomic alterations of YTHDF1 were investigated with the c-BioPortal database. The differential expression of YTHDF1 in urogenital cancers with different clinical characteristics was analyzed with the UALCAN database. YTHDF1 coexpression networks were studied by the LinkedOmics database.ResultsIn general, YTHDF1 expression was higher in tumors than in paired normal tissue in human cancers. YTHDF1 expression had strong relationships with prognosis, ICP, TMB, MSI, and neoantigens. YTHDF1 plays an essential role in the tumor microenvironment (TME) and participates in immune regulation. Furthermore, significant strong correlations between YTHDF1 expression and tumor immune-infiltrated cells (TILs) existed in human cancers, and marker genes of TILs were significantly related to YTHDF expression in urogenital cancers. TYHDF1 coexpression networks mostly participated in the regulation of immune response and antigen processing and presentation.ConclusionYTHDF1 may serve as a potential prognostic and immunological pan-cancer biomarker. Moreover, YTHDF1 could be a novel target for tumor immunotherapy.https://www.frontiersin.org/articles/10.3389/fonc.2021.607224/fullYTHDF1prognosistumor microenvironmentimmune infiltrationimmunotherapyhuman cancer |
| spellingShingle | Jian Hu Dongxu Qiu Anze Yu Jiao Hu Hao Deng Huihuang Li Zhenglin Yi Jinbo Chen Xiongbing Zu YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy Frontiers in Oncology YTHDF1 prognosis tumor microenvironment immune infiltration immunotherapy human cancer |
| title | YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy |
| title_full | YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy |
| title_fullStr | YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy |
| title_full_unstemmed | YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy |
| title_short | YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy |
| title_sort | ythdf1 is a potential pan cancer biomarker for prognosis and immunotherapy |
| topic | YTHDF1 prognosis tumor microenvironment immune infiltration immunotherapy human cancer |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.607224/full |
| work_keys_str_mv | AT jianhu ythdf1isapotentialpancancerbiomarkerforprognosisandimmunotherapy AT dongxuqiu ythdf1isapotentialpancancerbiomarkerforprognosisandimmunotherapy AT anzeyu ythdf1isapotentialpancancerbiomarkerforprognosisandimmunotherapy AT jiaohu ythdf1isapotentialpancancerbiomarkerforprognosisandimmunotherapy AT haodeng ythdf1isapotentialpancancerbiomarkerforprognosisandimmunotherapy AT huihuangli ythdf1isapotentialpancancerbiomarkerforprognosisandimmunotherapy AT zhenglinyi ythdf1isapotentialpancancerbiomarkerforprognosisandimmunotherapy AT jinbochen ythdf1isapotentialpancancerbiomarkerforprognosisandimmunotherapy AT xiongbingzu ythdf1isapotentialpancancerbiomarkerforprognosisandimmunotherapy |